Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Untch

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Biorxiv : the Preprint Server for Biology|July 19, 2024
RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitnessGnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, et al.
Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.
Thyroid : Official Journal of the American Thyroid Association|February 26, 2024
<i>RAS</i>-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active SurveillanceHannah J Sfreddo, Elizabeth S Koh, Karena Zhao, et al.
The Journal of Experimental Medicine|February 24, 2025
RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAsGnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, et al.
Surgery|October 10, 2025
Multifocality in sporadic medullary thyroid carcinoma is associated with low tumor grade and no difference in somatic driver mutations or overall survival when compared with unifocal tumorsAradhya Nigam, Michael A Mederos, Yagiz A Aksoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2021
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid CarcinomaBin Xu, Talia L Fuchs, Sara Ahmadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Histopathology|January 22, 2024
Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinomaYagiz A Aksoy, Bin Xu, Kartik Viswanathan, et al.
Nature Communications|June 15, 2022
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targetsBenjamin A Nacev, Francisco Sanchez-Vega, Shaleigh A Smith, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Biorxiv : the Preprint Server for Biology|July 19, 2024
RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitnessGnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, et al.
Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.
Thyroid : Official Journal of the American Thyroid Association|February 26, 2024
<i>RAS</i>-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active SurveillanceHannah J Sfreddo, Elizabeth S Koh, Karena Zhao, et al.
The Journal of Experimental Medicine|February 24, 2025
RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAsGnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, et al.
Surgery|October 10, 2025
Multifocality in sporadic medullary thyroid carcinoma is associated with low tumor grade and no difference in somatic driver mutations or overall survival when compared with unifocal tumorsAradhya Nigam, Michael A Mederos, Yagiz A Aksoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2021
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid CarcinomaBin Xu, Talia L Fuchs, Sara Ahmadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Histopathology|January 22, 2024
Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinomaYagiz A Aksoy, Bin Xu, Kartik Viswanathan, et al.
Nature Communications|June 15, 2022
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targetsBenjamin A Nacev, Francisco Sanchez-Vega, Shaleigh A Smith, et al.
Pageof 5